Effect of Intravenous Fentanyl on the Occurrence of Postoperative Nausea and Vomiting According to Time of Administration Around the End of Tonsillectomy With or Without Adenoidectomy

Sponsor
Yonsei University (Other)
Overall Status
Completed
CT.gov ID
NCT03343002
Collaborator
(none)
140
1
2
9
15.6

Study Details

Study Description

Brief Summary

Fentanyl is a commonly used drug for the prevention of emergence agitation and reduction in postoperative pain in children receiving tonsillectomy. However, fentanyl can cause postoperative nausea and vomiting (PONV), which is a main target side effect that medical staff strives to prevent. However, recent meta-analysis showed that the incidence of PONV may be different depending on the time of administration of fentanyl. However, the research design of patients enrolled in each study, such as the age, the name of the operation, and the method of anesthesia, is not identical. The aim of this study was to evaluate the efficacy and safety of fentanyl in patients undergoing tonsillectomy with a prospective randomized controlled trial. Secondary outcomes include incidence and severity of emergence agitation and anesthesia recovery time, postanesthesia care unit (PACU) time, side effects.

Condition or Disease Intervention/Treatment Phase
  • Drug: fentanyl at 10-15 min before end of surgery
  • Drug: fentanyl at end of surgery
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
140 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
Effect of Intravenous Fentanyl on the Occurrence of Postoperative Nausea and Vomiting According to Time of Administration Around the End of Tonsillectomy With or Without Adenoidectomy
Actual Study Start Date :
Nov 26, 2017
Actual Primary Completion Date :
Aug 27, 2018
Actual Study Completion Date :
Aug 27, 2018

Arms and Interventions

Arm Intervention/Treatment
Experimental: fentanyl at 10-15 min before end of surgery

Drug: fentanyl at 10-15 min before end of surgery
Label 2 syringe is filled with 1mcg/kg of fentanyl, label 1 syringe is filled with same amount of saline solution. If the surgeon notifies the anesthesiologist 10-15 minutes before the end of the operation, the syringe drug labeled 1 will be administered intravenously(that is, normal saline ). At the end of the surgery, the syringe drug labeled 2 is administered intravenously((that is, 1mcg/kg of fentanyl)

Active Comparator: fentanyl at end of surgery

Drug: fentanyl at end of surgery
Label 2 syringe is filled with 1mcg/kg of fentanyl, label 1 syringe is filled with same amount of saline solution. If the surgeon notifies the anesthesiologist 10-15 minutes before the end of the operation, the syringe drug labeled 1 will be administered intravenously(that is, normal saline ). At the end of the surgery, the syringe drug labeled 2 is administered intravenously((that is, 1mcg/kg of fentanyl)

Outcome Measures

Primary Outcome Measures

  1. Incidence of postoperative nausea and vomiting [In 10-minute increments from immediately(less than 3 min) after entering PACU to departure]

    Occurrence of nausea and vomiting- Described as yes/no (Observation of medical personnel or Subjective symptoms of the patient by the definition below) Nausea: "feeling of the urge to vomit" vomiting: "retching and any expulsion of liquid gastric contents"

Secondary Outcome Measures

  1. PAED scale score: *Pediatric Anesthesia Emergence Delirium scale: range 0-20 points. If the score is more than 12, it is considered to be EA occurrence. [In 10-minute increments from immediately(less than 3 min) after entering PACU to departure]

    *Pediatric Anesthesia Emergence Delirium scale: range 0-20 points. If the score is more than 12, it is considered to be EA occurrence.

  2. five-step EA scale: *five-step Emergence Agitation scale: range 1-5 score. If the score is 4 or more, it is regarded as EA occurrence. [In 10-minute increments from immediately(less than 3 min) after entering PACU to departure]

    *five-step Emergence Agitation scale: range 1-5 score. If the score is 4 or more, it is regarded as EA occurrence.

  3. FLACC score FLACC score (Face, Legs, Activity, Cry, Consolability scale): range 0-10. If the score is 4 or more, Pain control is considered necessary. [In 10-minute increments from immediately after entering PACU to departure]

  4. anesthesia recovery time [up to 1 day after end of surgery]

    <1> time until regular respiration is possible after end of surgery , <2>time to extubate after end of surgery, and <3>eye opening time in response to initial verbal command after end of surgery

  5. Occurrence of side effect [In 10-minute increments from immediately(less than 3 min) after entering PACU to departure]

    airway obstruction, laryngospasm, desaturation, drowsiness, pruritus, hypotension, bradycardia

Eligibility Criteria

Criteria

Ages Eligible for Study:
3 Years to 7 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Pediatric patients aged 3 to 7 years with ASA 1-II scheduled for tonsillectomy (or adenoidal tonsillectomy)
Exclusion Criteria:
    1. History of developmental disorder, cognitive impairment, cerebral palsy
    1. History of seizures(not simple febrile convulsions)
    1. Upper respiratory infections
    1. Structural airway disease predicting difficult airway
    1. History of an adverse reaction, including allergic reactions to fentanyl

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine Seoul Korea, Republic of 120-752

Sponsors and Collaborators

  • Yonsei University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Yonsei University
ClinicalTrials.gov Identifier:
NCT03343002
Other Study ID Numbers:
  • 4-2017-0813
First Posted:
Nov 17, 2017
Last Update Posted:
Aug 8, 2019
Last Verified:
Aug 1, 2019
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 8, 2019